Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...

The rise in GLP-1 drugs is undeniable. Morgan Stanley projects that by 2035, 24 million Americans, or 7% of the population, ...

Dublin, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The "Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Taking tiny doses of GLP-1 medication has been touted for weight management, perimenopause symptoms, even longevity. But is ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control, and adding savory flavors are ways that ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...